Stryker (NYSE:SYK) has completed the acquisition of MOLLI Surgical Inc., a private company specializing in wire-free soft tissue localization technology for breast conserving surgery. This acquisition strengthens Stryker's commitment to advancing surgical solutions in breast cancer care. The MOLLI 2 localization system offers ease of use and reliability for efficient surgical workflows. Key features include: - MOLLI Marker: Smallest on the market at 3.2 mm, detectable in dense breasts and through hematoma - MOLLI 2 tablet: Provides surgeons with real-time feedback including distance, visual, auditory, and 3D directional guidance This acquisition complements Stryker's existing breast cancer portfolio, which includes SPY fluorescence imaging technology for lymphatic mapping and lighted retractors.